NSE: JUBLPHARMA | BSE: 530019

Strong Performer, Getting Expensive

Download real time

1101.00 -17.40 (-1.56%)

High volume today

NSE 31 Oct, 2025 3:31 PM (IST)

17,536.8

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Jubilant Pharmova Ltd. share price target and research reports

Name: Latest research reports of Jubilant Pharmova Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Jubilant Pharmova Ltd.
Rating: 3
Author: ICICI Direct

Latest analyst research reports with target prices and PDF download for JUBLPHARMA, BSE:530019 Jubilant Pharmova Ltd.

Search Inside the pdf :

Jubilant Pharmova Ltd.

29 Oct 2022

1101.00

-1.56%

Jubilant Pharmova

Hold: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Direct

Number of FII/FPI investors decreased from 233 to 212 in Sep 2025 qtr

Jubilant Pharmova Ltd.

25 Oct 2022

1101.00

-1.56%

Mixed bag; valuations provide comfort

Buy: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Securities Limited

Jubilant Pharmova’s (Jubilant) Q2FY23 performance was a mixed bag with revenue declining 3.5% YoY to Rs16bn due to generics business and tapering of covid-related revenues but ahead of our estimated sales of Rs15bn.

Jubilant Pharmova Ltd. is trading above its 200 day SMA of 1038.5

Jubilant Pharmova Ltd.

03 Aug 2022

1101.00

-1.56%

Margin pressure continues

Accumulate: Jubilant Pharmova Ltd.

Target

ICICI Securities Limited

Jubilant Pharmova’s (Jubilant) Q1FY23 missed our estimates on the profitability front, while reported revenue was as expected. Revenues declined 11.2/5.0% YoY/QoQ to Rs14.5bn due to lower CDMO sales with covid-related deals tapering off. EBITDA margin declined 970bps/290bps YoY/QoQ to 13.3% (I-Sec: 15.5%) and adjusted PAT declined 70.7% YoY to Rs470mn.

Number of FII/FPI investors decreased from 233 to 212 in Sep 2025 qtr

Jubilant Pharmova Ltd.

03 Aug 2022

1101.00

-1.56%

Jubilant Pharmova

Sell: Jubilant Pharmova Ltd.

ICICI Direct

Jubilant Pharmova Ltd. is trading at high day volume of 544.0K.

Jubilant Pharmova Ltd.

08 Feb 2022

1101.00

-1.56%

Jubilant Pharmova

Hold: Jubilant Pharmova Ltd.

Target

ICICI Securities Limited

Revenue break up (FY21)- Formulations - 24%, Radiopharma and allergy therapy 38% and CDMO & API 33% Q3FY22 Results: Generics and CDMO business were affected due to multiple headwinds leading to reduction in operating leverage....

Number of FII/FPI investors decreased from 233 to 212 in Sep 2025 qtr

Jubilant Pharmova Ltd.

05 Feb 2022

1101.00

-1.56%

Weak 3Q, muted outlook; downgrade to Neutral

Neutral: Jubilant Pharmova Ltd.

Recommendation Target

Motilal Oswal

Jubilant Pharmova (JP) delivered 3QFY22 earnings far below our expectations, led by a weak Generics / Contract Development and Manufacturing Organization (CDMO) business and a sharp reduction in operating leverage. While the Radiopharma business posted YoY growth in 3QFY22, the recent surge in COVID cases has impacted the business on a QoQ basis. We cut our FY22E/FY23E/FY24E EPS estimate by 40%/45%/35% to factor in a) the adverse impact in the Generics business due to an import alert at Roorkee, b) pricing pressure in the US market, c) lower COVID-driven business, d) the...

Jubilant Pharmova Ltd. has gained 22.61% in the last 6 Months

Jubilant Pharmova Ltd.

25 Oct 2021

1101.00

-1.56%

Jubilant Pharmova

Hold: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Securities Limited

Formulations - 24% of FY21 revenues, Radiopharma and allergy therapy 38% and CDMO & API 33% of sales Q2FY22 Results: Below I-direct estimates, especially on the CDMO front....

Promoters initiated pledges of 5.40% of holdings in Sep 2025 qtr.

Jubilant Pharmova Ltd.

24 Jul 2021

1101.00

-1.56%

Radiopharma on a gradual recovery path

Buy: Jubilant Pharmova Ltd.

Target

Motilal Oswal

JP delivered in line earnings, despite a better than expected revenue in 1QFY22. The COVID-related business led to a strong YoY revenue growth. However, reduced number of lung procedures in the Radiopharma segment, increased price erosion in the Sartans portfolio, and price erosion in the base portfolio in the Generics segment led to lower-than-expected profitability, offsetting benefits of higher revenue. We have reduced our FY22E/FY23E EPS estimate by 14% each to factor in: a) delay in potential products on account of the import alert at Roorkee, b)...

Jubilant Pharmova Ltd. is trading at high day volume of 544.0K.

Jubilant Pharmova Ltd.

24 Jul 2021

1101.00

-1.56%

Jubilant Pharmova

Buy: Jubilant Pharmova Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors decreased from 233 to 212 in Sep 2025 qtr

Jubilant Pharmova Ltd.

19 Jun 2021

1101.00

-1.56%

Demand prospects favorable; execution remains the key

Buy: Jubilant Pharmova Ltd.

Motilal Oswal

Jubilant Pharmova (JP) hosted an investor/analyst meet to discuss the business and strategic initiatives in key business segments. With the COVID disruption behind in key markets, JP expects radiopharma sales...

Jubilant Pharmova Ltd. is trading above its 200 day SMA of 1038.5

Is Jubilant Life Sciences Ltd. worth buying?

383 Votes:

Buy 80.42%

Sell 11.23%

Hold 8.36%